SAT1 and glioblastoma multiforme: Disarming the resistance

3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Glioblastoma multiforme is the most common and most detrimental form of brain tumor, with a current survival time of as little as 14 months. We have recently identified a novel mechanism of therapeutic resistance based on overexpression of the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase, which promotes DNA repair via chromatin modification.

Cite

CITATION STYLE

APA

Brett-Morris, A., Mislmani, M., & Welford, S. M. (2015). SAT1 and glioblastoma multiforme: Disarming the resistance. Molecular and Cellular Oncology, 2(3). https://doi.org/10.4161/23723556.2014.983393

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free